We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $186M
1-Year Est. Return 155.23%
This Fund
S&P 500
This Quarter Est. Return
-11.59%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$154M
AUM Growth
-$5.82M
Cap. Flow
+$26.1M
Cap. Flow %
16.9%
Top 10 Hldgs %
99.79%
Holding
12
New
1
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$45.5M

Top Sells

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$9.23M
2
REPL icon
Replimune Group
REPL
+$5.91M
3
ENGN icon
enGene Therapeutics
ENGN
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Miscellaneous 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAX
1
Bicara Therapeutics
BCAX
$1.56B
$38.4M 24.91%
2,204,650
– –
NUVB icon
2
Nuvation Bio
NUVB
$2.29B
$34.8M 22.55%
13,072,340
– –
UPB
3
Upstream Bio Inc
UPB
$326M
$33.5M 21.71%
+2,036,293
New +$45.5M
REPL icon
4
Replimune Group
REPL
$1.36B
$23.9M 15.51%
1,975,203
-486,116
-20% -$5.91M
LXEO icon
5
Lexeo Therapeutics
LXEO
$368M
$7.79M 5.06%
1,184,636
-1,171,268
-50% -$9.23M
ALMS
6
Alumis Inc
ALMS
$1.27B
$5.13M 3.33%
653,223
– –
IMA
7
ImageneBio Inc
IMA
$56.9M
$3.69M 2.39%
187,427
– –
ENGN icon
8
enGene Therapeutics
ENGN
$124M
$3.5M 2.27%
526,357
-550,000
-51% -$4.27M
IMUX icon
9
Immunic
IMUX
$166M
$1.79M 1.16%
178,816
– –
SANA icon
10
Sana Biotechnology
SANA
$949M
$1.38M 0.89%
843,750
– –
ENGNW icon
11
enGene Therapeutics Warrants
ENGNW
$271K 0.18%
321,502
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$57.8K 0.04%
251,270
– –

Similar funds

LBC
Leigh Baldwin & Co Cazenovia, New York $186M AUM 40.09% 1-Year Est. Return
GWCM
Godshalk Welsh Capital Management Radnor, Pennsylvania $186M AUM 18.63% 1-Year Est. Return
FWM
Fingerlakes Wealth Management Ithaca, New York $186M AUM 30.5% 1-Year Est. Return
LOIP
Live Oak Investment Partners Austin, Texas $186M AUM 19.39% 1-Year Est. Return
TFA
Tranquilli Financial Advisor Clinton, New Jersey $186M AUM 18.12% 1-Year Est. Return
NCM
Northland Capital Management Virginia, Minnesota $186M AUM 16.43% 1-Year Est. Return
GPI
General Partner Inc Pittsburgh, Pennsylvania $186M AUM 25.15% 1-Year Est. Return
MWM
Melfa Wealth Management Westborough, Massachusetts $185M AUM 17.73% 1-Year Est. Return

Omega Fund Management's Q4 2024 Portfolio in Review

As of Q4 2024, Omega Fund Management held 12 positions worth $154M, down 3.6% from $160M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management deployed $26.1M of net new capital in Q4 2024, opening 1 new position. Its largest new stake was Upstream Bio Inc: 2,036,293 shares worth $33.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Lexeo Therapeutics, an estimated $9.23M trimmed.

  • Omega Fund Management's largest Q4 2024 buy was Upstream Bio Inc: 2,036,293 shares worth $33.5M.
  • Omega Fund Management's biggest Q4 2024 reduction was Lexeo Therapeutics, cutting an estimated $9.23M.
  • Omega Fund Management's ten largest holdings make up 100% of its $154M portfolio in Q4 2024.
  • Omega Fund Management opened 1 new position and closed 0 in Q4 2024.
  • Omega Fund Management's portfolio value fell 3.6% quarter-over-quarter to $154M.

Based on Omega Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.